KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gilead Sciences (GILD) Equity Ratio (2016 - 2025)

Gilead Sciences' Equity Ratio history spans 17 years, with the latest figure at 0.38 for Q4 2025.

  • For Q4 2025, Equity Ratio rose 16.95% year-over-year to 0.38; the TTM value through Dec 2025 reached 0.38, up 16.95%, while the annual FY2025 figure was 0.38, 16.95% up from the prior year.
  • Equity Ratio reached 0.38 in Q4 2025 per GILD's latest filing, up from 0.37 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.38 in Q4 2025 to a low of 0.28 in Q1 2021.
  • Average Equity Ratio over 5 years is 0.33, with a median of 0.34 recorded in 2022.
  • Peak YoY movement for Equity Ratio: decreased 24.32% in 2021, then rose 16.95% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.31 in 2021, then rose by 8.31% to 0.34 in 2022, then increased by 9.07% to 0.37 in 2023, then fell by 10.52% to 0.33 in 2024, then increased by 16.95% to 0.38 in 2025.
  • Per Business Quant, the three most recent readings for GILD's Equity Ratio are 0.38 (Q4 2025), 0.37 (Q3 2025), and 0.35 (Q2 2025).